SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

BMN 351

BMRN·BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 1/2
Time to market
At least 4-6 years away. The drug is in Phase 1/2 with no pivotal trial yet initiated. If the year-end 2026 update is positive, a Phase 3 trial could start in 2027-2028, with potential approval in the 2030-2032 timeframe, assuming success.
Why 2/10
The next catalyst is a program update expected by year-end 2026 (Q4 2026), which is a soft milestone rather than a hard binary event like a PDUFA or pivotal readout. BMN 351 is an early Phase 1/2 program at a large diversified biotech with over $1B in quarterly revenue, so this single drug represents a very small fraction of BioMarin's enterprise value. ImpactScore is 2.
Actionable Insight NEUTRAL

Watch for BioMarin's year-end 2026 program update on BMN 351, which is expected to include clinical data from the 6 mg/kg and 9 mg/kg cohorts of the Phase 1/2 study. Positive dystrophin expression data could support advancement to a pivotal trial, while any safety signal or disappointing efficacy would be a setback. However, given BMN 351's small weight in BioMarin's diversified portfolio, even a clear outcome is unlikely to move the stock more than a few percent.

Price Chart

Loading chart...

Executive Summary

BMN 351 (nivudirsen) is BioMarin's Phase 1/2 antisense oligonucleotide therapy for Duchenne muscular dystrophy (DMD) patients with genetic mutations amenable to exon 51 skipping, representing roughly 13% of the DMD population. Initial Phase 1/2 data showed 5.0% mean absolute dystrophin expression at week 25 in the 9 mg/kg cohort with acceptable safety, and the company expects to provide a program update by year-end 2026. The drug faces entrenched competition from Sarepta's already-approved Exondys 51 (eteplirsen), though Sarepta's next-generation SRP-5051 was discontinued in 2024 over safety concerns. For BioMarin, a diversified rare-disease company that just posted its first $1B+ revenue quarter, BMN 351 is a small early-stage pipeline asset with limited near-term stock impact potential.

How It Works

BMN 351 is an antisense oligonucleotide (a short, lab-made piece of genetic material) designed to treat Duchenne muscular dystrophy (DMD) in patients with a specific genetic mutation. DMD is caused by a lack of the protein dystrophin, which muscles need to stay intact. BMN 351 works by 'skipping over' a faulty section (exon 51) of the dystrophin gene during protein production, allowing cells to produce a shortened but still functional version of dystrophin. This is similar to the naturally occurring, milder form of the disease called Becker muscular dystrophy. The drug is given as a weekly intravenous infusion.

Trial Status

The Phase 1/2 study (351-201, NCT06280209) is an open-label, dose-escalation trial in ambulatory boys aged 4-10 with DMD amenable to exon 51 skipping. Interim data through 25 weeks showed acceptable safety and positive dystrophin changes. A Phase 2 open-label extension study (NCT07573631) is also recruiting to assess long-term safety and functional efficacy. BioMarin expects to share a clinical update for the 6 mg/kg and 9 mg/kg cohorts by year-end 2026.

The Two-Sided Case

▲ Bull Case5
BMN 351 targets a novel binding site in exon 51 and produces near-full-length dystrophin (similar to the milder Becker form of MD), which may offer a functional advantage over the truncated dystrophin from eteplirsen.
Initial Phase 1/2 data showed 5.0% mean absolute dystrophin expression at week 25 in the 9 mg/kg cohort with acceptable safety, and PK/PD modeling predicts dystrophin levels will continue to rise toward steady state.
Sarepta's next-gen exon 51 candidate SRP-5051 was discontinued, leaving a potential opening for BMN 351 as a potentially improved therapy in this genetic subpopulation (~13% of DMD patients).
BioMarin is a seasoned rare-disease developer with deep regulatory and commercial expertise (Vimizim, Voxzogo, etc.), increasing the probability of successful development.
The Phase 2 open-label extension study (NCT07573631) is already recruiting, indicating BioMarin is moving the program forward efficiently.
▼ Bear Case5
BMN 351 is still in early Phase 1/2 with limited patient data; the 5.0% mean absolute dystrophin expression at week 25 is modest and may not translate into meaningful functional improvement.
Sarepta's Exondys 51 (eteplirsen) is already FDA-approved for exon 51 skip-amenable DMD, giving it a major commercial head start and real-world safety track record.
The DMD exon 51 skipping field has seen setbacks: Sarepta discontinued its next-gen SRP-5051 in 2024 due to safety concerns (hypomagnesemia, kidney issues), highlighting the regulatory risk for this mechanism.
BMN 351 is a tiny part of BioMarin's pipeline; the company generated over $1B in quarterly Q3 2026 revenue from approved products, so even positive BMN 351 data would have limited impact on the stock.
BioMarin's stock has been under pressure (down ~5% in post-market on Nov 2, 2026) and the company cut full-year guidance, suggesting broader headwinds.

Upcoming Catalysts

  • Program update by year-end 2026 (Q4 2026): clinical data from the 6 mg/kg and 9 mg/kg cohorts of the Phase 1/2 study

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BIOMARIN PHARMACEUTICAL INC 8-K BMRN ·Originating report

Sources · 10

Hover a chip for the title
1 biomarin.com2 medical.biomarin.com3 medical.biomarin.com4 biomarin.com5 sec.gov6 sarepta.com7 tradingkey.com8 marketbeat.com9 biomarin.com10 sec.gov